Literature DB >> 24076348

Involvement of the spinal NALP1 inflammasome in neuropathic pain and aspirin-triggered-15-epi-lipoxin A4 induced analgesia.

Q Li1, Y Tian, Z-F Wang, S-B Liu, W-L Mi, H-J Ma, G-C Wu, J Wang, J Yu, Y-Q Wang.   

Abstract

Neuroinflammation plays an important role in nerve-injury-induced neuropathic pain, but the explicit molecular mechanisms of neuroinflammation in neuropathic pain remain unclear. As one of the most critical inflammatory cytokines, interleukin-1β (IL-1β) has been regarded as broadly involved in the pathology of neuropathic pain. The inflammasome caspase-1 platform is one primary mechanism responsible for the maturation of IL-1β. Lipoxins, a type of endogenous anti-inflammatory lipid, have proved to be effective in relieving neuropathic pain behaviors. The present study was designed to examine whether the inflammasome caspase-1 IL-1β platform is involved in chronic constriction injury (CCI)-induced neuropathic pain and in lipoxin-induced analgesia. After rats were subjected to the CCI surgery, mature IL-1β was significantly increased in the ipsilateral spinal cord, and the inflammasome platform consisting of NALP1 (NAcht leucine-rich-repeat protein 1), caspase-1 and ASC (apoptosis-associated speck-like protein containing a caspase-activating recruitment domain) was also activated in spinal astrocytes and neurons, especially at the superficial laminae of the spinal dorsal horn; The aspirin-triggered-15-epi-lipoxin A4 (ATL), which shares the potent actions of the endogenous lipoxins, was administered to the CCI rats. Repeated intrathecal injection with ATL markedly attenuated the CCI-induced thermal hyperalgesia and significantly inhibited NALP1 inflammasome activation, caspase-1 cleavage, and IL-1β maturation. These results suggested that spinal NALP1 inflammasome was involved in the CCI-induced neuropathic pain and that the analgesic effect of ATL was associated with suppressing NALP1 inflammasome activation.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ALX; ASC; ATL; Boc2; CARD; CCI; CSF; DMSO; ELISA; GAPDH; GFAP; HRP; IL; IgG; MMP; NALP; NALP1 inflammasome; NAcht leucine-rich-repeat protein; NeuN; Neuron-specific Nuclear Protein; PBS; PWL; SEM; TBST; apoptosis-associated speck-like protein containing a caspase-activating recruitment domain; aspirin-triggered-15-epi-lipoxin A4; butoxycarbonyl-Phe-Leu-Phe-Leu-Phe; caspase; caspase-activating recruitment domain; cerebrospinal fluid; chronic constriction injury; dimethyl sulfoxide; enzyme-linked immunosorbent assay; glial fibrillary acidic protein; glyceraldehyde 3-phosphate dehydrogenase; horseradish peroxidase; i.t.; immunoglobulin G; interleukin; intrathecal; lipoxin A4 receptor; metalloproteinase; neuropathic pain; paw withdrawal latency; phosphate-buffered solution; standard error; tris-buffered saline with tween

Mesh:

Substances:

Year:  2013        PMID: 24076348     DOI: 10.1016/j.neuroscience.2013.09.028

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  24 in total

1.  In vivo and systems biology studies implicate IL-18 as a central mediator in chronic pain.

Authors:  Kiran Vasudeva; Yoram Vodovotz; Nabil Azhar; Derek Barclay; Jelena M Janjic; John A Pollock
Journal:  J Neuroimmunol       Date:  2015-04-28       Impact factor: 3.478

2.  Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation.

Authors:  V Kaushal; R Dye; P Pakavathkumar; B Foveau; J Flores; B Hyman; B Ghetti; B H Koller; A C LeBlanc
Journal:  Cell Death Differ       Date:  2015-03-06       Impact factor: 15.828

3.  Pannexin-1 Up-regulation in the Dorsal Root Ganglion Contributes to Neuropathic Pain Development.

Authors:  Yuhao Zhang; Geoffroy Laumet; Shao-Rui Chen; Walter N Hittelman; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2015-04-29       Impact factor: 5.157

4.  AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome.

Authors:  Pedro Bullón; Elísabet Alcocer-Gómez; Angel M Carrión; Fabiola Marín-Aguilar; Juan Garrido-Maraver; Lourdes Román-Malo; Jesus Ruiz-Cabello; Ognjen Culic; Bernhard Ryffel; Lionel Apetoh; François Ghiringhelli; Maurizio Battino; José Antonio Sánchez-Alcazar; Mario D Cordero
Journal:  Antioxid Redox Signal       Date:  2015-09-16       Impact factor: 8.401

5.  Circulating Lipids and Acute Pain Sensitization: An Exploratory Analysis.

Authors:  Angela Starkweather; Thomas Julian; Divya Ramesh; Amy Heineman; Jamie Sturgill; Susan G Dorsey; Debra E Lyon; Dayanjan Shanaka Wijesinghe
Journal:  Nurs Res       Date:  2017 Nov/Dec       Impact factor: 2.381

6.  Gastrodin Inhibits Inflammasome Through the STAT3 Signal Pathways in TNA2 Astrocytes and Reactive Astrocytes in Experimentally Induced Cerebral Ischemia in Rats.

Authors:  Yue Sui; Ligong Bian; Qinglong Ai; Yueyi Yao; Mali Yu; Huiqing Gao; Aidan Zhang; Xiyue Fu; Lianmei Zhong; Di Lu
Journal:  Neuromolecular Med       Date:  2019-06-19       Impact factor: 3.843

7.  Lipoxin A4 Reduces Inflammation Through Formyl Peptide Receptor 2/p38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats.

Authors:  Zongduo Guo; Qin Hu; Liang Xu; Zhen-Ni Guo; Yibo Ou; Yue He; Cheng Yin; Xiaochuan Sun; Jiping Tang; John H Zhang
Journal:  Stroke       Date:  2016-01-05       Impact factor: 7.914

Review 8.  NLRP3 inflammasomes are involved in the progression of postoperative cognitive dysfunction: from mechanism to treatment.

Authors:  Shuai Zhao; Fan Chen; Dunwei Wang; Wei Han; Yuan Zhang; Qiliang Yin
Journal:  Neurosurg Rev       Date:  2020-09-12       Impact factor: 3.042

Review 9.  The inflammasome as a target for pain therapy.

Authors:  H Zhang; F Li; W-W Li; C Stary; J D Clark; S Xu; X Xiong
Journal:  Br J Anaesth       Date:  2016-12       Impact factor: 9.166

Review 10.  Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain.

Authors:  Christopher R Donnelly; Amanda S Andriessen; Gang Chen; Kaiyuan Wang; Changyu Jiang; William Maixner; Ru-Rong Ji
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.